Abstract: Acute lymphoblastic leukemia (ALL) is one of the major forms of leukemia that affects mostly adolescent individuals. The main cause of the development of ALL is not known though several important signal transduction pathways have been reported with functional abnormality in all the cases. Crucial signalling pathways reported in ALL include PI3K/Akt, Notch, Wnt, mTOR, JaK/Stat, etc. Over the past several decades important progress has been made in the management of ALL, however, relapses and post therapy survival ratio has not improved much. This brings the need for understanding the biology and mechanism involved in ALL occurrences and find new molecular targets for better treatment options and risk-adapted therapies to improve the outcome of ALL patients.
Introduction
Acute lymphoblastic leukemia (ALL) is a disorder that occurs from the clonal expansion of malignant lymphoid progenitor cells of either T or B cell origin. T-ALL is a biologically heterogeneous disease with respect to phenotype, gene expression profile and activation of aberrant cell signal transduction pathways. Although prevalence of the disorder is seen in both children and adults, reports assign it as a most common childhood malignancy. Steady progresses have been achieved towards effective treatment of childhood T-ALL, with 65-75% cure rates in children for a span of 5 years. Poor prognosis of adult lymphoblastic leukemia, the expense, complexity and toxic side effects employing current therapeutic regimens owing to long-term multi-agent treatments still remains unplugged (Chiaretti et al. 2004; Pui et al. 2011) .
The exact pathogenetic events leading to ALL still remain a question. However, various factors from sporadic (e.g., genetic lesions or mutations) to congenital (e.g., exposure to agents like pesticides, powerfrequency magnetic fields, wrong addictions) are purported to confer over-activation of key 'pro-oncogenes' like MYC, p53 and so on. These genes, however, under normal developmental conditions are indispensable participants of most signatory pathways of development, activation and differentiation that lead blood cells to maturity (Ahlbom et al. 2000; Bonnet et al. 2011) . Cells implicated in ALL have clonal rearrangements in their immunoglobulin or T-cell receptor genes and express antigen-receptor molecules and other differentiation linked cell-surface glycoproteins that largely recapitulate those of immature lymphoid progenitor cells within the early developmental stages of normal T and B lymphocytes (Li et al. 2005; Gutierrez et al. 2010) . The punch-line of current research in the direction of leukemia pathogenesis is to critically study the multiple cellular pathways that are involved in survival, differentiation and proliferation of the leukemia blasts. This contemporary analysis can be thereby implicated in devising selectively targeted treatments against the particular alteration on which the leukemia clones are dwelling by attaining unlimited self-renewal (Pui & Evans 1998; Biondi et al. 2000) . The intent of this review is to critically dig into the signalling pathways, e.g., phosphotidylinositol-3OH-kinase (PI3K)/Akt, Notch, mammalian target of rapamycin (mTOR), Janus kinase/signal transducer and activator of transcription (JaK/Stat) and WNT, which are prevalent in ALL.
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Aberrant pathways reported in ALL
Akt Pathway in ALL battle Akt -a ser/thr kinase enzyme is omnipresent in cell survival. With its participation as a key enzyme in several signal transduction pathways of cell proliferation and apoptosis, Akt certainly makes a good cause of enticement in investigations related to cell immortality. The PI3K/Akt pathway in a normal cell receives its activation signal with binding of growth factors to receptor tyrosine kinase. This binding facilitates PI3K phosphorylation that nails its activation. A membrane bound event thereafter by PI3K leads to generation of PI3P -the second messenger through activation of PI2P (Tezzari et al. 2007 ). PI3P which is thereby released, anchors Akt to the plasma membrane exposing this enzyme to phosphorylation at two regulatory residues, serine and threonine (Cantley 2002) . Four different isoforms of Akt have been reported that differ slightly in the localization of their regulatory phosphorylation sites.
Akt signals pro-proliferative message correlating anti-apoptotic note through inhibitory phosphorylation of Bad, glycogen synthase kinase-3, caspase-9 (Luo et al. 2004 ) and simultaneous up regulation of NF-κB via IKK phosphorylation, activation of mTOR pathway, also activating phosphorylation of Mdm2 oncogene protein facilitating its nuclear transport (Yilmez et al. 2006) (Fig. 1) . Reports with T-ALL suggest constitutive activation of Akt through phosphorylation independent of growth factors (Barata et al. 2005) .
In another study (Lo et al. 2009 ) it has been reported that inactivation of Src homology 2 domain containing inositol phosphatase (SHIP) 1 could play a central role in the deregulation of Akt pathway and tumourigenesis, perhaps in conjugation with phosphatase and tensin homolog located on chromosome 10 (PTEN) inactivation. Comparative genomic hybridization and sequence analysis of DNA samples from children with T-ALL (Gutierrez et al. 2009 ) revealed PTEN deletion as more adverse therapeutic consequences than mutational disruptions that preserve the phosphatase domain.
In ALL PTEN and SHIP form the regulatory gate in controlling Akt phosphorylation by PI3K/PDK1. Reports suggest chromosomal deletion or mutation in the genes of PTEN/SHIP with cases of T-ALL and an obvious correlation could therefore be drawn towards the over-activation of PI3K/Akt pathway (Baldwin 2001; Zhang et al. 2006) . PTEN mutations resulting in protein truncation have been identified most frequently in T-ALL cell lines established from relapsed patients (30.4%) than in diagnostic clinical specimens (5.2%), which point out that PTEN gene deletion is a late event human T-ALL (Pahl 1999; Zhang et al. 2006) . The hyper-activation of PI3K/Akt, however, with respect to PTEN/SHIP gene lesions has been shown to be non-synonymous. Studies with T-ALL patient samples show that primary T-ALL cells expressed normal PTEN mRNA levels and that PTEN down-modulation was mostly in a non-deletional posttranslational manner. In addition, T-ALL cells were shown to harbour constitutively high levels of reactive oxygen species, decreased PTEN lipid phosphatase activity resulting from casein kinase 2 overexpression and hyper-activation which down-modulates PTEN activity together with high reactive oxygen species levels (Silva et al. 2008) (Fig. 1) .
These findings add significant support to the rationale for the development of therapies targeting PTEN-PI3K-Akt pathway in T-ALL.
Notch pathway
Notch signalling pathway plays an inevitable role in facilitating commitment of multipotent hematopoietic progenitors to the T-cell lineage, early during hematopoiesis (Radtke et al. 1999; Harper et al. 2003; Pui et al. 2004 ). In a majority of studies Notch has been implicated in tumourigenesis of solid tumours Leong & Karsan 2006) , apart from the pathogenesis of haematological malignancies. Notch can transmit either pro-oncogenic or tumour suppressive signals depending on the specific Notch paralogue and the cell type, extracellular environment and signal intensity. In mammals, it has been reported that four Notch proteins (Notch 1-4) are encoded by different genes. They, however, show a considerable amount of sequence similarity to Drosophila Notch. The five Notch activating ligands (Delta-like-1, 3 and 4 and Jagged 1-2) that are also homologues to Drosophila Delta/Serrate genes (Leong & Karsan 2006) are all expressed at the cell surfaces in either monomeric or heterodimeric forms (Zweidler-McKay & Pear 2004) . In ER, Notch is expressed as a single tandem protein sequence which has both the trans-membrane Notch region (tm-N) and the intracellular portion of Notch (ic-N). This single tandem sequence undergoes S1 proteolytic cleavage following which its heterodimerization occurs. This modified Notch receptor is then expressed onto the membrane (Pui et al. 2008) . Here receptor activation occurs through ligand binding via the EGF-like repeats (present on both receptor and ligand), where transmembrane Notch faces the exterior, while the intracellular Notch faces cytosolic side (Pui et al. 1999; Allman et al. 2002) . Following ligand-receptor binding, a conformational change leads to two proteolytic cleavages by ADAM protease and γ-secretase. The second cleavage releases ic-N and thereby is translocated into the nucleus (Fig. 1) . Notch specific genes receive activation when ic-N forms a transcription activating complex with multiple (protein) subunits mainly by binding CSL, MAML1-3, n300 and co-activators (Allman et al. 2001) . Downstream Notch responder genes include MYC oncogenes, Deltex1 (notch signal modulator), HES1 (hairy/enhancer of split), hairy related (HET, HEY) gene family members NPARP, Pre-Tα and CD25 (Palomero et al. 2006; Weng et al. 2006) . These genes are all participants of cell proliferation, differentiation and survival modulation (Leong & Karsan 2006) . Mouse model studies provide strong evidences Interaction between molecules of PI3K/Akt, Notch, Wnt and mTOR signalling pathways activated in ALL is represented. The central molecules of these pathways are activated through several external stimuli including cytokines and interleukins that bind to their respective receptors and thereby activate signalling events downstream. Constitutive activation of major kinases of these pathways also occur through activating mutations in molecules upstream or via chromosomal translocation. Here such mutations are shown by red boxes. These pathways also regulate apoptosis and therefore in deregulated conditions drive cells to leukemogenesis. Potential sites of interaction between these pathways are represented here. These pathways interact and cross-regulate each other in both direct and indirect manners. Green dotted lines represent up-regulation event, whereas down regulation is represented by black dotted lines. Molecules inactivated by phosphorylation are depicted by black circles with P written in white. Activating phosphorylations are represented in yellow boxes with P written in black.
towards the pro-oncogenic role of Notch signal in T-ALL development. Truncated Notch1 expressing constitutive ic-N, transduced into immunodeficient mice via bone marrow cells showed 100% penetrance leading to the development of T-cell leukemia (Pear 1996; Deftos et al. 2000) . In flow cytometric analysis of blood cells from healthy and leukemic types, bone marrow cells, and established leukemic lines, it was reported that Notch1 and Jagged1 exhibit consistently high expression state in T and B subsets apart from monocytes, stating the potential it holds in various leukemia progression (Kanamori et al. 2012; Yatim et al. 2012) .
The aberrant constitutive expression of Notch1 has been linked to the pathogenesis of T-ALL after genomewide gene expression profiling and assessment of the rearrangement status of the T-cell receptor loci (Staal et al. 2007 ) and characterization of the t(7;9)(q34;q34.3) translocation, which is a rare recurrent chromosomal rearrangement present in less than 1% of human T-ALL cases (Chiaramonte et al. 2005; Grabher et al. 2006; Palomero et al. 2008) . Studies of patient samples strengthened the role of Notch1 in pathogenesis of T-ALL with over 50% of T-ALL samples exhibiting ligand independent activation of the receptor or increased ic-N1 protein stability owing to activating Notch1 mutations Breit et al. 2006; Mansour et al. 2006 Mansour et al. , 2007 . Two types of mutations were reported to be prevalent in human T-ALL: extracellular domain mutations that increase ic-N1 production and C-terminal mutations that sustain ICN1 action (Aster 2005) . A more recent report with human T-ALL suggests (Rodig et al. 2008 ) that activating Notch1 mutations are concentrated in exons 26 and 27, encoding the HD domain, and in exon 34, encoding the PEST domain, which is important for proteasomal degradation of ic-N1.
Aside mutations/translocations there is a recent report on the role of DLL4 ligand dependent regula-tion of Notch3 receptors in T-ALL (Indraccolo et al. 2010) . With all the studies linking aberrant Notch1 signalling effectively to the pathogenesis of T-ALL, it makes a promising therapeutic target towards T-ALL treatment (Radtke et al. 2005; Palomero & Ferrando 2009) . Small molecule inhibitors of γ-secretase (GSIs) capable of blocking Notch1 activation have prompted clinical trials to test their effectiveness against T-ALL ( Tzoneva & Ferrando 2012) . Initial studies on human T-ALL cell lines harbouring activating mutations in Notch1 treated with GSIs confirms that inhibition of Notch signalling arrests cells at G0/G1 phase (Palomero et al. 2006; Lewis et al. 2007; Rao et al. 2009 ). However, this efficacy has been questioned as GSI treatment failed to have similar effects on some cell lines despite high prevalence of Notch1 mutations and the presence of high levels of ic-N (O' Neil et al. 2007 ).
The functional interchangeability of mammalian Notch receptors (Notch1-4) in normal and pathophysiologic contexts such as cancer is unsettled. We find that the activated ic-N1-4 all support T cell development in mice and thymic organ culture. However, unlike ic-N1-3, ic-N4 fails to induce T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and is unable to rescue the growth of Notch1-dependent T-ALL cell lines. We conclude that the leukemogenic potentials of Notch receptors vary, and that this functional difference stems in part from divergence among the highly conserved ankyrin repeats, which influence the transactivation of specific target genes involved in leukemogenesis (Aster et al. 2011) .
This puzzle gradually became more understood with studies focusing the down-stream pathways that follow Notch1 activation (Apperley 2007a,b; Mellor & Callaghan 2008) . Several groups have hypothesized a feed-forward-loop circuit consisting Notch1-cMYC that regulate oncogenic and developmental effects of Notch signalling (Palomero et al. 2006) . Though constituting only a small fraction of transcription network a relationship between developmental signals upstream of Notch1 and proliferation signal upstream MYC establishes the importance of Notch1 and c-MYC in T-cell transformation (Klinakis et al. 2006; Weng et al. 2006; Sharma et al. 2007 ). Notch1 activation is collaborated with another transcriptional co-activator ZMIZ1 which activates Stat, and has been shown to have a potential role in driving c-MYC activation for leukemogenesis (Rakowski et al. 2012) . Inhibition of ZMIZ1 not only slowed the leukemic cell growth, it also sensitized the cells to Notch inhibitors, throwing light on the potential of ZMIZ1-Notch in leukemia therapy.
More experiments conducted to unravel the mechanism of chemo-resistance has connected this Notch1 phenomenon to be p 53 dependent (Demarest et al. 2008) . It was seen that ic-N inhibited p 53 activating phosphorylations at Ser15, Ser20 and Ser392 and also its nuclear translocation. This effect was, however, connected via a PI3K/Akt/mTOR pathway, also via eIF4E (Mungamuri et al. 2006) . PTEN mutations have been reported sporadically in leukemias and lymphomas (Sakai et al. 1998; Aggerholm et al. 2000; Yilmaz et al. 2006; Maser et al. 2007) . Also in the same light analysis of global gene expression signatures associated with GSI sensitivity or resistance in a panel of leukemia cell lines using oligonucleotide microarrays identified decreased levels of the PTEN tumour suppressor gene as the most consistent transcriptional feature associated with GSI-resistant cell lines (Palomero et al. 2007 ). Therefore, there exists an interconnection between PI3K-Akt pathway and Notch1 pathway where in case of blocking Notch1 by GSI, the oncogenic addiction of T-cells is shifted to Akt up-regulation due to PTEN mutation . A contradiction to this hypothesis, however, was put forward by Medyouf et al (2007) when they addressed the same issue using a genetically defined mouse retroviral transduction/bone marrow transplantation model and observed primary murine leukemias to remain dependent on Notch1 signalling despite PTEN loss. Thirteen cases of primary T-ALL samples tested on the same notion strengthened their view that no correlation exists between non-functional PTEN and resistance to Notch inhibition, instead PTEN loss alongside Notch1 mutation accelerate leukemia onset in murine model, but does not relieve primary T-ALL cells of their "Notch" addiction (Medyouf et al. 2010 ).
TLX1 and Notch were found to synergistically regulate transcription in T-ALL by augmenting expression of MYC, in GSI treated cells; TLX1 was shown to produce stable Myc protein (Riz et al. 2010 ). TLX1 is not normally expressed in the hematopoietic system, its inappropriate expression due to chromosomal translocations involving T cell receptor genes is associated with about 30% of adult and approximately 8% of childhood T-ALL cases (Ralowski et al. 2011 ).
Wnt pathway
With the growing discrepancies in prognosis of several pleiotropic diseases, modern researchers are focusing on unearthing the causes that dismantle the regulations of critical pathways involved in development, proliferation and differentiation processes of the cell. The Wnt signalling pathway is one such cascade that regulates crucial aspects of cell fate determination, cell migration, cell polarity, neural patterning and organogenesis during embryonic development (Wodarz et al. 1998; Yamaguchi 2001; Logan & Nusse 2004) . This pathway has also been shown essential to stem cell renewal and for ordered hematopoietic development (Reya et al. 2003; Willert et al. 2003; Duncan et al. 2005; Petropoulos et al. 2008) .
The Wnt pathway transcends activation signals through the Fzd receptor, to several intra-cellular signalling cascades including the Wnt/β-catenin dependent/canonical pathway and non-canonical pathway which could be further grouped as cell polarity pathway and the Wnt/Ca 2+ pathway, respectively (Habas & Dawid 2005 Studies surfaced presence of constitutive expression of Wnt-signalling proteins in T-ALL cases and somatic mutations in key regulatory genes of the Wnt pathway of many solid tumours, which cumulatively give good reasons to believe that uncontrolled Wnt signals could cause leukemias (Weerkamp et al. 2006) . Recent data using genome-wide gene expression profiling and assessment of rearrangement status of the T-cell receptor loci confirm the notion that T-ALL cells are the malignant counterparts of normally developing T-cells in the thymus (Staal et al. 2007) . A Wnt signalling molecule Wnt3A was reported to activate the canonical pathway in both primary B-ALL cells and B-ALL leukemia cell lines (Khan et al. 2007; Nygren et al. 2007 ). Promotion of self-renewal capacity of human ALL cells of the T-cell type by Wnt/β-catenin signalling was established by Kawaguchi et al. (2008) . They have shown that Wnt3A stimulation of some T-ALL cells promote self renewal of leukemic stem/progenitor cells but not that of whole cell population (Kawaguchi et al. 2008) . A path-breaking study established the involvement of Wnt in early stages of T-ALL development, applying various transgenic and tissue specific conditional-knockout mouse models. The conditional deletion of exon 3 particularly in β-catenin lead to a constitutively active form of β-catenin that could then no longer be phosphorylated and broken down. As from double-positive stage and onwards canonical Wnt signals are negligible there is massive uncontrolled Wnt signalling during late thymocyte differentiation (Weerkamp et al. 2006) . This leads to the development of aggressive T-cell lymphomas that can invade the bone marrow and are transplantable into irradiated recipient mice. Both Notch and Wnt are major players in T-cell development pathways regulating at different stages of development. However, Wnt is persistent till the immature single positive stage, whereas Notch signal requirement stops at the DN3 stage. Hence, both Notch and Wnt pathways lead to malignant transformations owing to mutations leading to arrest of differentiation and overexpression of target oncogenes, i.e., c-Myc that are common to both.
Notch and Wnt signalling pathways are both necessary for the self-renewal of hematopoietic stem cells. Hematopoietic stem cells have shown a remarkable upregulation of Notch target genes Hes1 and Dtx1 when stimulated with Wnt3a (Duncan et al. 2005) . It was also shown that both Wnt4 and Notch1 expression were necessary to turn early T-lineage cells into SP T-cells (Rafik et al. 2005) . What could be of interest is to identify if these two pathways are independent of each other in the oncogenic transformation of T-ALL or there exists interdependence in lymphogenesis. mTOR pathway mTOR pathway is another key regulator of cell growth and proliferation of cell. It is a central pathway playing hand-in-hand with other important cell survival and differentiation cascades like Akt, Notch and the MAPK pathway. mTOR projects uniqueness in integrating signals from nutrients, energy status, growth factors and regulating an array of cell functions from metabolism, autophagy to ribosome biogenesis (Martin et al. 2004; Meijer & Codogno 2004) . A Ser/Thr kinase is the central element of the pathway (Kim et al. 2003 ) and understanding this pathway is yet to be well defined. However, its complexity and crucial involvement in major cellular processes is strengthening gradually. Sitting at the junction of critical bio-signalling cascades involved in cell survival, development, progression and maturation, mTOR pathway forms an obvious subject of keenness with respect to ALL, especially in cases of T-ALL. Evidences of perturbed mTOR functioning in ALL cells (Chan et al. 2007 ) has strengthened the hypothesis, thereby making a strong ground for investigations in leukemia pathogenesis and prognosis.
Studies with mTOR inhibitor, rapamycin highlights the presence of two separate multi-protein complexes. One that binds FKBP12-rapamycin complex is composed of mTOR, GβL and raptor, whereas the rapamycin insensitive complex consists of mTOR, GβL and rictor (Cafferkey et al. 1993; Kunj et al. 1993; Sabatini et al. 1994) , both delivering distinct functions. Studies found that the rictor -mTOR complex (also known as TORC1) -modulates the phosphorylation of protein kinase Cα and actin cytoskeleton, suggesting that this aspect of TOR signalling is conserved between yeast and mammals (Sarbassov et al. 2004 ) and also plays a pivotal role in Akt/PKB activation (Sarbassov et al. 2005; Jacinto et al. 2006) . Growth regulators SK6K1 and 4E-BP1 are the major downstream effectors of the raptor complex (also known as TORC1) of the mTOR pathway and are activated through phosphorylations at specific sites, i.e., Thr412 or Thr401 (Yonezawa et al. 2004 ) and Thr389 (Schalm & Blenis 2002) ; and at least six phosphorylation sites have been identified in human 4E-BP, including Thr37, Thr46, Ser65, Thr70, Ser83 and Ser112 (Fadden et al. 1997; Heesom et al. 1998; Long et al. 2005) .
Upstream of the mTOR complex there are two GTPase activating proteins TSC1 and TSC2, that downmodulate Rheb -a GTP binding protein, which binds to and activates the raptor-mTOR complex. Its activation is down-modulated by TSC1 and TSC2. The story of regulation of rictor-mTOR complex is still inside a black box.
In some studies inactivation of PTEN, p53 and NF1 has been related to activation of mTOR-raptor (Neshat et al. 2001) . The regulation of cell cycle is correlated to downstream read-outs of mTOR pathway -eIF4E and S6K1. Blocking the mTOR pathway with rapamycin blocked the G1 progression of various human carcinoma and lymphocyte cells (Chan, 2004) . As reviewed in many studies mTOR pathway is evolutionarily conserved and a central co-ordinator of the fundamental processes like cell growth and cell proliferation (Crespo & Hall 2002; Jacinto & Hall 2003; Oldham & Hafen 2003) . mTOR functions through interactions with a number of signalling pathways including PI3K/Akt, Ras, TCL1, BCR/ABL, IKK and nutrient sensing via rag-GTP binding proteins (Shaw & Cantley 2006; Kharas et. al. 2008; Teachey et al. 2009 ). The proto-oncogenic signalling through mTOR has been linked to a constitutive activation of Notch1. In some studies, inhibition of Notch activation through a GSI rendered mTOR in an inactive state leading the leukemic cells to a quiescent state (Chan et al. 2007 ). This cell cycle arrest was in fact rescued by transfection of cells with c-Myc that lead to mTOR up-regulation. So, one important aspect of mTOR activation was involvement of Notch pathway via c-Myc that acts as an intermediate, in T-ALL cells (Chan et al. 2007; Lee et al. 2012; Shepherd et al. 2013) . mTOR forms two complexes, mTORC1 and mTORC2 (Bhaskar & Hay 2007) . The main targets of mTORC1 are S6K1 and 4E-BP1 (inhibitor of capdependent translation). The activation of mTOR by c-Myc occurs through mTORC1 complex, which is PI3K/Akt independent (Wullschleger et al. 2006 ). Also, it was reported in the same study that activated Akt phosphorylates TSC2 that leaves Rheb to activate mTOR. Downstream genes transcribed by mTOR pathway include c-Myc, cyclin D and ornithine decarboxylase. mTOR facilitates the elimination of Cdk inhibitor p27 kip1 through interactions with p34cdc2 allowing cell cycle progression under the regulation of Cdks including cyclin-A (Faivre et al. 2007 ).
Occurrence of chemoresistance in an mTORdependent manner has come up over the past few years. These reports have concluded involvement of several apoptosis regulating genes, such as p53, Akt, icN-1, etc., in mTOR-mediated chemoresistance (Mungamuri et al. 2006) . In most T-ALL cases, constitutive activation of PI3K/Akt/mTOR has been reported and mTOR therefore forms a potential target for T-ALL treatment. mTOR inhibitors have been used for many years now and a side effect of these drugs is the inhibition of a negative feedback pathway, which results in Akt activation (Sun et al. 2005) . Some investigators have been targeting to block mTOR in combination with other inhibitors targeting different signalling targets. In one such study, it was reported that rapamycin potentiates the inhibitory activity of other signalling inhibitors and the cytotoxic effects of the conventional drugs dexamethasone and doxorubicin (Barista et al. 2004) . In a similar study, the therapeutic potential of a dual PI3K/mTOR inhibitor PI-103 was shown to be more potent than individual inhibitor for either PI3K or mTOR (Chiarini et al. 2009 ). RAD001 is another oral drug which was used to treat B-ALL, but some cases of cytotoxicity was reported (Decker et al. 2008) .
These studies indicate that multi-targeting of mTOR pathway with existing drugs or with other interconnecting pathways intends to present a better way of addressing mTOR deregulation in the treatment of T-ALL.
JaK/Stat in leukemia
The JaK-Stat pathway is universal and essential to cytokine receptor signalling. It was initially discovered in the studies on gene induction by interferon, and since has been a well understood signalling cascade O'Shea et al. 2002) .
The cell surface cytokine receptors lack intrinsic tyrosine kinase activity. Cytokine binding to the receptor leads to its dimerization/oligomerization and activation of associated JaK tyrosine kinase. Its phosphorylation by JaK exposes docking sites for the SH2 (Src homology 2) domains of the Stats. The SH2 domain is required for Stat activation and dimerization (Fu & Zhang 1993; Shuai et al. 1994) , while the N-terminal region of Stat is involved in the formation of Stat tetramers (Xu et al. 1996) and tyrosine dephosphorylation (Shuai et al. 1996) . Stats are cytoplasmic transcription factors, which are recruited following tyrosine, and in some cases, serine phosphorylation on key residues (by the JAKs and other closely associated kinases) that causes their transit into the nucleus. SHP2 (a ubiquitously expressed SH2 domain containing PTP) plays an essential role in hematopoiesis and lymphopoiesis. Homozygous deletion of exon 3 of SHP2, including the N-SH2 domain-encoding region (amino acids 46-110) (SHP2∆/∆), resulted in embryonic lethality at midgestation with a defect in mesoderm patterning (Arrandale et al. 1996; Saxton et al. 1996) . Gene disruption studies have described the severe and wide involvement of JaK-Stat in regulating hematopoietic cell function and immune system development and functioning (Nosaka et al. 1995; Park et al. 1995; Neubaur et al. 1998; Parganas et al. 1998; Grossman et al. 1999) . In mammalian system there are four JaKs (JAK1, JAK2, JAK3, and TYK2) and seven Stat proteins (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6) have been identified so far (Darnell 1997) . JaK-Stat deregulation has been studied in both lymphoid and myeloid malignancies with a significant TEL-JaK2 fusion (Lacronique et al. 1997; Carron et al. 2000) . Mice transduced with this fusion have shown to develop fatal mixed myeloproloferative and T-cell lympho-proliferative leukemia (Schwaller et al. 1998) . Ba/F3 cell lines expressing TEL-JaK2 fusion protein were also shown to become growth factor independent. The early pre-B cell ALL was reported with translocation t(9;12)(q24;p13) whereas in case of atypical chronic myeloid leukemia a complex translocation t(9;15:12)(p24;q15;p13) has been implicated (Ho et al. 1999) .
More appreciable is the constitutive expression of Stat proteins in most leukemias of both lymphoid and myeloid type. For example the fusion protein TELJaK2 is associated not only with the activation of STAT1 and STAT5, but also triggers Erk2 activation through its association with Shc and Grb2 (Carron et al. 2000; Franstsve et al. 2001) . Reports suggest constitutive activation of STAT1, STAT3 and STAT5 in T-ALL patient samples. Also ALL primary cells show deactivation of SHP1 via its methylation, which is a negative regulator of JaK/Stat pathway (Gouilleux et al. 1996; Chim et al. 2004) . In a separate and more recent study (Qazi & Uckun 2010) , primary leukemia cells from infant ALL patients were shown to express significantly higher levels of genes for cytokines that mediate their biological effects through stimulation of the JaK-Stat signal transduction pathway including interleukin 1a, interleukin 1b, interleukin 2, and interleukin 7, and also identified JAK3 as an attractive molecular target for disrupting the constitutively deregulated anti-apoptotic STAT3 and STAT5 signalling pathways in infant ALL cells.
Apart from these genetic aberrations, extrinsic factors prevalent in the leukemic milieu play a pivotal role in the JaK-Stat pathway activation and leukemogenesis. As shown by Barata et al. (2005) , pro-leukemic IL-7 activate JAK1, JAK3 and STAT5 in T-ALL cells. IL-9 is a multifunctional TH2 cytokine that was shown to be involved in T cell tumourigenesis in mouse and in humans (Kelleher et al. 1991; Merz et al. 1991; Fischer et al. 2003) . Recently it was reported that IL-9Rα and IL-2Rβ homodimers efficiently mediate constitutive activation of ALL-associated JAK1 mutants (Hornakova et al. 2000) . Despite studies conducted towards involvement of JaK-Stat towards leukemia prognosis, much still remains to be done in patient samples and therefore in a promising field in combating leukemia.
Conclusions
It is evident that considerable progresses have been achieved in the prognosis and therapy of ALL. Still one of the major concerns prevails with the level of clonal heterogeneity and complex diversity of genetic abnormality reported in patients with ALL. Alterations in signalling pathways play distinctive roles in the development and progression of ALL.
In T-ALL, the pathways deregulated frame the major signalling molecules that play vital roles in the differentiation and maturation of T cells from the hematopoietic stem cells in the thymus. The major pathways that are clearly deregulated in ALL include PI3K/Akt, Notch, Wnt, mTOR and JaK/Stat pathways. Normally these pathways operate in the thymus in a strictly regulated manner since the key molecules of these developmental pathways are also reported protooncogenes like c-Myc, p-Akt, p53, etc. Some studies have shown that over-activation of PI3K/Akt pathway correlates with chromosomal deletion or mutation in the genes of PTEN/SHIP with cases of T-ALL (Zhang et al. 2006) . In light with these findings various reports have also shown the efficacy of inhibitors of PI3K pathway in the management of T-ALL patients ). The malignant transformation of normal developing thymocytes occurs with the juxtaposition of these oncogenes with T-cell receptor loci, as reported in majority of ALL patients. The exact events that could cause the over-activation of key proteins of these pathways are not yet fully understood. The biggest contribution of such activation is that the pathways are all interlinked, rendering a cross activation of other key components of related signalling circuits. Notch, Wnt, JaK/Stat and mTOR all are activated in the development stages of T-cell development in ALL. PTEN mutation is thought to amplify Notch1 signals through the PI3K/Akt/mTOR pathways. As a result, clinical trials are underway combining GSI with agents that target collaborative pathways, such as mTOR inhibitors. Aberrant JaK signalling was first linked with T-ALL in the context of the t(9;12)(p24;p13) translocation encoding the constitutively active ETV6-JAK2 kinase fusion oncoprotein. More recently, activating mutations in JAK1 and JAK3 have been reported in T-ALLs. The output of Notch signals has been reported to link activation of JaK/Stat and Wnt pathways as well, under normal developmental stages of T-cell development as well as in T-ALL studies (Hayward et al. 2005; Hurlburt et al. 2007) . So the feed forward loop that has been reported throughout different studies till date, leads to the conjecture that PI3K/Akt, mTOR, Notch, JaK/Stat and Wnt work together in a consorted manner to contribute towards leukemic transformation of T-cells.
In case of B-ALL, PI3K signalling regulates the development of bone marrow B cell precursors, as well as the differentiation and development of B cell subsets (Beer-Hammer et al. 2010) . Constitutive activation of the PI3K, Akt and the mTOR (PI3K/Akt/mTOR) network is a feature of B-pre ALL, where it strongly influences cell growth and survival (Neri et al. 2013 ). Many groups have documented high basal levels of Akt and mTOR activation in B cell leukemias, B cell lymphomas, and multiple myeloma cells. Genomewide gene analysis array using microarray, candidate gene and second generation sequencing have also provided a detailed light on the genetic basis of B-ALL development (Mullighan 2012) . Several genetic lesion type categorize B-ALL disease subtype with specific oncogenic activation related to each type of chromosomal ablation. For example, the BCR-ABL oncoprotein strongly activates PI3K/Akt signalling and mTOR activity in Philadelphia chromosome-positive (Ph + ) leukemias (Janes et al. 2010) . Collectively, these genetic aberrations include loss-of-function mutations involving genes that regulate lymphoid development leading to maturation arrest of B-cells (a characteristic of B-ALL) and mutations that inactivate tumour suppressors or drive kinase signalling pathways (i.e. PI3K/Akt, Notch, Wnt, mTOR and JaK/Stat pathways). These aberrant pathways as in case of most T-ALL cases, drive the B-ALL population growth and progression.
Taken together, it can be concluded that identifi-cation of molecular targets for better treatment of the disease could be done by analysing the different types of intracellular aberrant signalling pathways that prevails in ALL patients. Nonetheless, tailor-made therapies involving the use of signalling specific antagonists of these key pathways would be of utmost importance in designing the treatment strategies of ALL, which is key to reducing the cytotoxicity of patients and increase in post-treatment survival rates. Therefore such caseto-case approach will steer the future maximum cure rate dreamt for leukemia today.
